After Vaccine Recalculation, AstraZeneca Looks To Move On But Likely Faces Extra US FDA Scrutiny

 
• By Andrew McConaghie
  
AZ Vaccines
AZ expects to file with the US FDA in the coming weeks, and is likely to face extra questions about its safety and efficacy data.

More from Clinical Trials

More from R&D